Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
THUMP domain-containing protein 2 (THUMPD2) is an RNA methyltransferase that forms a complex with TRMT112 to specifically catalyze the S-adenosylmethionine (SAM)–dependent N(2)-methylation of guanosine at position 72 (m²G72) in U6 small nuclear RNA (snRNA), a core component of the major spliceosome[1][2][3]. This post-transcriptional RNA modification is essential for efficient pre-mRNA splicing, particularly affecting introns with suboptimal splice sites, and impacts global mRNA processing in human cells[1][2][3]. Loss of THUMPD2-mediated U6 m²G72 methylation impairs splicing activity and can lead to widespread alternative splicing events, induction of nonsense-mediated decay, and is associated with retinal pathologies including age-related macular degeneration[1][2]. THUMPD2 is ubiquitously expressed in multiple cell types and tissues and operates mainly in the nucleus, consistent with its role in spliceosome function[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on THUMP domain-containing protein 2 (THUMPD2).